Following the acquisition of Mindspace in December 2020, Numinus now offers psychedelic assisted psychotherapy across 3 different locations in Canada. As well as offering Ketamine-assisted psychotherapy, Numinus is hoping to offer other psychedelic assisted psychotherapy treatments, pending the approval by Health Canada on the use of these substances in a Special Access Programme (SAP). Numinus is also undertaking 2 ‘compassionate access’ clinical trials for MDMA assisted psychotherapy for PTSD treatment (in collaboration with MAPS) and Psilocybin assisted psychotherapy for substance abuse disorders.

Numinus Bioscience has a state of the art lab and research facility in BC, Canada, which is revenue generating.  It holds a controlled drugs and substances license issued by Health Canada to allow the possession, production, assembly, sale, export and delivery for a wide variety of psychedelic compounds and natural source materials.

The company listed on the TSX-V in May 2020, and has completed several successful fundraisings since then, most recently in March 2021 raising $35m in an upsized bought deal.